Table 1.
The dual role of inflammasomes in different types of cancers.
| The type of cancer | Inflammasome | The effects of the inflammasome | Reference | |
|---|---|---|---|---|
| Inflammaso-mes in tumor suppression | colitis-associated colon cancer | NLRP3 | Inhibition of tumorigenesis through activation of ASC, IL-18 and caspase1 | (38, 39) |
| lung adenocarcinoma | NLRP1 | Inhibition of tumorigenesis by increasing the expression level of NLRP1 | (40) | |
| colorectal cancer | NLRP1 | Inhibition of tumorigenesis through regulation of IL-18 and IL-1β | (41) | |
| NLRC4 | Inhibition of tumorigenesis by suppressing cell proliferation | (42) | ||
| AIM2 | Inhibition of tumorigenesis by impairing colon cancer stem cell proliferation and promoting cell death | (43) | ||
| malignant melanoma | NLRC4 | Inhibition of tumorigenesis by promoting the production of IFN-γ in CD4+ and CD8+ T cells | (44) | |
| breast cancer | AIM2 | Inhibition of tumorigenesis by leading to cancer cell apoptosis | (45) | |
| liver cancer | AIM2 | Inhibition of tumorigenesis by suppressing the mTOR-S6K1 signaling pathway | (46) | |
| Inflammaso-mes in tumor promotion | metastatic melanoma | NLRP3 | Promotes tumorigenesis by suppressing NK cell and T cell activity and recruiting MDSCs and Tregs | (47) |
| NLRP1 | Promotes tumorigenesis by enhancing NLRP1 inflammasome activation and inhibiting apoptosis | (48) | ||
| lung adenocarcinoma | NLRP3 | Promotes tumorigenesis by recruiting tumor-associated macrophages and releasing IL-1β and IL-1α | (49) | |
| AIM2 | Promotes tumorigenesis by regulating the expression of the cell cycle proteins through the AIM2/IL-1β/STAT3 signaling pathway | (50) | ||
| breast cancer | NLRP3 | Promotes tumorigenesis through activation of NLRP3 and release of IL-1β | (51) | |
| NLRC4 | Promotes tumorigenesis through adipocyte-mediated VEGFA expression | (52) | ||
| NLRP1 | Promotes tumorigenesis by inducing epithelial-mesenchymal transformation | (53) | ||
| multiple myeloma | NLRP1 | Promotes tumorigenesis by releasing IL-18 and increasing the production of MDSCs | (54) | |
| cutaneous squamous cell carcinoma | AIM2 | Promotes tumorigenesis by increasing the expression of cell cycle regulatory genes | (55) |